2015/12/17: Sygnis AG

SYGNIS AG significantly expands its Asian distribution network by signing three additional agreements with PhileKorea and Pharma Tech Korea as well as Axil Scientific for Singapore

SYGNIS AG today announced that it has signed three additional non-exclusive distribution agreements with PhileKorea, Pharma Tech Korea and Axil Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Korea and Singapore and thereby significantly expands its Asian footprint.


2015/12/15: Apogenix GmbH

Apogenix to Present at J.P. Morgan Healthcare Conference

Apogenix ... announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.


2015/12/14: Cosmo Pharmaceuticals S.p.A.

Cosmo & Ferring Pharmaceuticals enter into licensing agreement for CORTIMENT® MMX® (budesonide) in Japan

Cosmo Pharmaceuticals S.A. announced today that it has signed a licensing agreement with Ferring Pharmaceuticals, granting Ferring the rights to CORTIMENT® MMX® for Japan.


2015/12/10: Sygnis AG

SYGNIS AG successfully completes Rights Offering and Private Placement

SYGNIS AG today announced that the Company has successfully completed its rights offering and the subsequent private placement.


2015/12/03: Sygnis AG

SYGNIS AG concludes agreement with Lucigen Corp. as a distributor for their NGS portfolio focused on the clinical oncology research market in the U.S.

SYGNIS AG today announced that it has signed a distribution agreement with Lucigen Corp. (Middleton, Wisconsin, USA) for the commercialization of SYGNIS’ proprietary product portfolio in the USA. 


2015/12/02: Sygnis AG

SYGNIS AG signs distribution agreement with Mayflower Bioscience for the US market

SYGNIS AG today announced that it has signed a distribution agreement with Mayflower Bioscience LLC (St. Louis, USA) for the commercialization of SYGNIS’ proprietary product portfolio in the USA.


2015/11/17: Sygnis AG

SYGNIS AG plans to issue new shares to finance further growth and commercialization of proprietary product portfolio

SYGNIS AG today resolved, with the approval of the Supervisory Board, to increase the Company’s share capital by up to EUR 3.9 million by issuing up to 3,855,694 new shares in order to finance the expansion of its commercialization activities, especially to the US, among other things. 


2015/11/06: Sygnis AG

SYGNIS reports nine month results for the period ended September 30, 2015

SYGNIS AG today reported results for the nine months ended September 30, 2015. 


2015/11/03: CureVac GmbH

CureVac raises $110 Million in a private placement

CureVac today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.
CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG). 


2015/10/30: Cosmo Pharmaceuticals S.p.A.

Mochida concludes phase III trials for Lialda® in Japan and files for registration

Cosmo Pharmaceuticals S.A. announced today that it has been informed by Mochida Pharmaceutical Co., Ltd., that Mochida has concluded the phase III clinical trials necessary for the submission of the registration in Japan and that Mochida had filed the NDA with the Japanese Ministry of Health, Labour and Welfare (MHLW)...


2015/10/13: Apogenix GmbH

Apogenix to Present at Three Upcoming International Conferences

Apogenix, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the BIO Investor Forum, the Sofinnova Japan Biopharma Partnering Conference, and the German Equity Forum.


2015/10/01: Sygnis AG

SYGNIS to present its innovative TruePrime™ and SunScript™ technologies for DNA amplification and sequencing at the ASHG 2015 in Baltimore

SYGNIS AG today announced that it will present its proprietary portfolio of TruePrime™ and SunScript™ technologies for DNA amplification and sequencing at the Annual Meeting of the American Society of Human Genetics (ASHG), the ASHG 2015, which will be held from October 6 – 10, 2015 in Baltimore, Maryland.


2015/09/17: Sygnis AG

SYGNIS AG signs distribution agreement with LABGENE Scientific for Switzerland

SYGNIS AG today announced that it has signed a distribution agreement with LABGENE Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Switzerland.


2015/09/15: Sygnis AG

SYGNIS Announces Global Launch of SunScript™ One Step Reverse Transcriptase-PCR Kit

SYGNIS AG today announced the global launch of SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit, the second product of its SunScript™ product line for parallel transcription and amplification of genomic information for a multitude of applications in molecular biology and diagnostics research.


2015/09/10: Sygnis AG

SYGNIS to present its innovative Trueprime™ technology at the Single Cell Genomics Conference 2015

SYGNIS AG today announced that it will present its proprietary TruePrime™ technology to experts from universities, corporations, associations and governmental agencies at the Single Cell Genomics Conference 2015.


2015/09/04: Cosmo Pharmaceuticals S.p.A.

FDA approves Cosmo’s submucosal injectable composition SIC 8000

Cosmo Pharmaceuticals S.p.A. announced today that the FDA has approved its request for marketing authorization of SIC 8000, its submucosal injectable composition. 


2015/08/26: immatics GmbH

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc.,  a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.


2015/08/25: Sygnis AG

SYGNIS AG signs non-exclusive distribution agreement for Australia with GeneWorks Pty Ltd

Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing (NGS) and single cell analysis (SCA) applications


2015/08/25: immatics GmbH

MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology

Collaboration Aims to Develop Novel Antibody-Based Therapies Targeting Tumor-Associated Peptides Derived From Intracellular Proteins 


2015/08/20: Sygnis AG

SYGNIS AG signs distribution agreement with Chinese Nanodigmbio Co. Ltd.

SYGNIS AG today announced that it has signed a distribution agreement with Nanodigmbio Co. Ltd. for the commercialization of SYGNIS’ proprietary product portfolio in China.


2015/08/13: Sygnis AG

SYGNIS reports half-year results for the period ended June 30, 2015

SYGNIS AG today reported results for the first six months ended June 30, 2015.


2015/08/12: WILEX AG

WILEX AG announces discontinuation of collaboration between its subsidiary Heidelberg Pharma and Roche

WILEX AG was informed today that Roche is discontinuing its partnership with the WILEX subsidiary Heidelberg Pharma GmbH with respect to their collaboration in the field of antibodytargeted amanitin conjugates (ATACs). 


2015/08/04: CureVac GmbH

Collaboration to Develop mRNA Vaccines Expands

CureVac ... today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation.


2015/07/30: Cosmo Pharmaceuticals S.p.A.

Cosmo reports exceptional profits and beats guidance by 18 months

Cosmo Pharmaceuticals S. A. (SIX: COPN) announced today its half-year results for the period ended 30 June 2015.


2015/07/28: Apogenix GmbH

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

Apogenix ... announced today that it has entered into an agreement with R-Biopharm ... to develop companion diagnostic tests for Apogenix’ lead drug candidate APG101.


2015/07/15: Apogenix GmbH

Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China

Apogenix ... announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences ... for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.


2015/07/14: WILEX AG

WILEX publishes Half-yearly Financial Report

WILEX AG today published its financial report on the first six months of 2015 (1 December 2014 - 31 May 2015). 


2015/07/13: joimax GmbH

FDA Clearance for joimax EndoLIF On-Cage: 3D-Printed Fusion Implant

The German company joimax ... today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Endoscopic Lumbar Interbody Fusion, or EndoLIF ®  On-Cage.


2015/07/09: Sygnis AG

Shareholders support Management proposals at SYGNIS’ AGM with large majority 

At the Annual General Meeting (AGM) of SYGNIS AG held on 8 July 2015 shareholders representing 59 percent of the capital approved all proposals of the Management with a large majority. 


2015/07/07: CureVac GmbH

CureVac publishes promising clinical data of its mRNA cancer immunotherapy

CureVac ... today announced that a Phase I/IIa study of the company’s mRNA cancer immunotherapy (CV9103) in advanced castration-resistant prostate cancer was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. 


2015/06/22: Cosmo Pharmaceuticals S.p.A.

Cosmo announces setting of price range for Cassiopea’s IPO on SIX Swiss Exchange

Cosmo Pharmaceuticals S.A. (SIX: COPN) has announced today that the price range for the initial public offering of its 97% owned subsidiary Cassiopea SpA has been set at CHF 30 to CHF 40 per offered share.


2015/06/17: Sygnis AG

SYGNIS AG signs non-exclusive distribution agreement with Scandinavian Biotop Oy for Finland

SYGNIS AG today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio with Biotop Oy for Finland.


2015/06/09: Cosmo Pharmaceuticals S.p.A.

Cosmo announces launch of Cassiopea’s IPO on SIX Swiss Exchange

Cosmo Pharmaceuticals S.A. (SIX: COPN) (“Cosmo”) announced today that its majority-owned subsidiary Cassiopea SpA (the “Company”) intends to conduct an initial public offering (the “Offering”) and seek a listing on SIX Swiss Exchange. 


2015/06/08: Sygnis AG

SYGNIS announces global launch of TruePrimeTM RCA kit for the direct amplification of circular DNA targets

SYGNIS AG today announced the global launch of TruePrimeTM RCA kit, the third product of its TruePrimeTM product line for the amplification of circular DNA targets.


2015/06/03: Apogenix GmbH

Apogenix appoints Peter Willinger as new CFO

Apogenix,  a  next  generation  immuno-oncology company, announced today the appointment of Peter Willinger as Chief Financial Officer.


2015/06/03: Sygnis AG

SYGNIS AG announces Genetrix S.L. has taken over all shares from Genetrix Life Sciences AB to become new majority shareholder

SYGNIS AG today announced that Genetrix S.L. has informed the Company that it has transferred all common shares currently held byGenetrix Life Sciences AB to Genetrix S.L. 


2015/05/13: Sygnis AG

SYGNIS reports results for the first quarter 2015

SYGNIS AG today announced its financial results for the first quarter of 2015, ended 31 March 2015.


2015/05/04: Sygnis AG

SYGNIS signs non-exclusive distribution agreement with Cambridge Bioscience Ltd. for UK and Ireland

SYGNIS AG today announced a distribution agreement with Cambridge Bioscience for the commercialization of SYGNIS’ proprietary product portfolio in the UK and Ireland.


2015/04/29: Sygnis AG

SYGNIS reports financial results for fiscal year 2014

SYGNIS AG today reported results for the fiscal year ending 31 December 2014. 


2015/04/23: WILEX AG

Results of Heidelberg Pharma’s research cooperation with MD Anderson Cancer Center published in Nature journal

WILEX AG today announced that pioneering study results on the Antibody Targeted Amanitin Conjugates (ATACs) technology have been published in the peer-reviewed journal Nature ...


2015/04/22: Sygnis AG

SYGNIS appoints Dr. Miguel-Antonio Viribay as Vice President Sales and Marketing

SYGNIS AG today announced that Dr. Miguel-Antonio Viribay has joined SYGNIS and will assume responsibility for the further development, implementation and execution of sales and marketing strategies as Vice President Sales and Marketing.


2015/04/20: Sygnis AG

SYGNIS Announces Global Launch of its Second Product Line: SunScript™ Reverse Transcriptase

SYGNIS AG today announced the global launch of SunScript™ Reverse Transcriptase, the Company’s second product line for a multitude of applications in molecular biology and diagnostics research.


2015/04/09: WILEX AG

WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences

WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH will present at two upcoming scientific conferences. 


2015/04/08: WILEX AG

WILEX AG successfully completes rights issue

The shareholders of WILEX AG exercised their subscription and oversubscription rights for all of the 1,486,732 new no-par value bearer shares for EUR 2.80 per share by the end of the subscription period on 07 April 2015. 


2015/03/26: WILEX AG

WILEX announces financial figures for the 2014 financial year and reports on course of business

WILEX AG today published its financial results and annual report for the 2014 financial year (1 December 2013 – 30 November 2014). 


2015/03/25: Cosmo Pharmaceuticals S.p.A.

Record profits & operating revenues for Cosmo in 2014

Cosmo Pharmaceuticals S.A. today announced its results for the year ended 31 December 2014. 


2015/03/25: Sygnis AG

SYGNIS AG to Present at Major Scientific Conferences in Europe and the U.S.A.

SYGNIS AG today announced that the Company will present its revolutionary TruePrimeTM technology for primer-free whole genome amplification at two major European scientific conferences in March and April 2015 hosted by EMBO/EMBL in Heidelberg, Germany as well as at the AACR Annual Meeting in Philadelphia, PA, U.S.A.


2015/03/19: Cosmo Pharmaceuticals S.p.A.

Record profits & operating revenues for Cosmo in 2014

Cosmo Pharmaceuticals S.A. (SIX: COPN) today announced first results for the year ended 31 December 2014.


2015/03/18: Sygnis AG

SYGNIS signs non-exclusive distribution agreement with SOPACHEM for TruePrime™ product family in Belgium

SYGNIS AG today announced a distribution agreement with SOPACHEM for the commercialization of the TruePrime™ product family developed by SYGNIS and designed for whole genome amplification (WGA) in Belgium.


2015/03/16: Cosmo Pharmaceuticals S.p.A.

Cosmo announces the start of trading of the shares after the redomiciliation of the Company

Cosmo Pharmaceuticals S.A. announced today, that the shares after redomiciliation of the Company start trading today after the Regulatory Board of the SIX Swiss Exchange has approved the listing of the redomiciled company Cosmo Pharmaceuticals S.A. on the Main Standard of SIX. 


2015/03/13: Cosmo Pharmaceuticals S.p.A.

Cosmo communicates final results of withdrawal process and execution modalities

Cosmo Pharmaceuticals S.p.A. announces the results of the preemptive offer to Cosmo shareholders of the shares with respect to which cash exit rights were exercised in connection with the resolution on the relocation of the registered seat from Italy to Luxembourg adopted by the Extraordinary Shareholders’ Meeting on November 14, 2014. 


2015/03/05: CureVac GmbH

The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 

The Bill & Melinda Gates  Foundation and CureVac today announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac ...


2015/03/04: joimax GmbH

joimax Receives 510(k) Clearance for Percusys Pedicle Screw-Rod System

The  German  company joimax ... today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Percusys  percutaneous pedicle screw-rod system.


2015/03/02: Cosmo Pharmaceuticals S.p.A.

Cosmo & Santarus file lawsuit against Alvogen for patent infringement of Uceris patents

Cosmo Pharmaceuticals SpA informs that Santarus, Inc., a wholly owned subsidiary of Salix Pharmaceuticals, Ltd., and its subsidiary, Cosmo Technologies Limited (“Cosmo”), the licensor, commenced a lawsuit against generic drug maker Alvogen Pine Brook, Inc. (“Alvogen”) ...


2015/02/25: WILEX AG

WILEX subsidiary Heidelberg Pharma receives research grant from the European Union

WILEX AG today announced that its subsidiary Heidelberg Pharma has been awarded a research grant from the European Union as part of the European Training Network (ETN) MAGICBULLET. 


2015/02/24: Cosmo Pharmaceuticals S.p.A.

Cosmo & Santarus file lawsuit against Actavis for patent infringement of Uceris patents

Cosmo Pharmaceuticals SpA informs that Santarus, Inc., a wholly owned subsidiary of Salix Pharmaceuticals, Ltd., and its subsidiary, Cosmo Technologies Limited (“Cosmo”), the licensor, commenced a lawsuit against generic drug maker Actavis, Inc. (“Actavis”) ...


2015/02/23: Sygnis AG

SYGNIS Announces Global Launch of the Second Kit from its TruePrime™ Product Line: TruePrime™ WGA Kit

SYGNIS AG today announced the global launch of TruePrime™ WGA kit, the second product of its TruePrime™ product line for whole genome amplification (WGA).


2015/02/18: Sygnis AG

SYGNIS AG signs initial distribution agreement for the North American market for TruePrime™ Single Cell WGA Kit with Canadian D-MARK BIOSCIENCES

SYGNIS AG today announced that it has signed a nonexclusive distribution agreement for its proprietary TruePrime™ Single Cell WGA Kit with D-MARK BIOSCIENCES for the North American market.


2015/02/03: Cosmo Pharmaceuticals S.p.A.

Cosmo and Santarus file lawsuit against Par for patent infringement of Uceris patents

Cosmo Pharmaceuticals SpA informs that Santarus, Inc., a wholly owned subsidiary of Salix Pharmaceuticals, Ltd., and its subsidiary, Cosmo Technologies Limited (“Cosmo”), the licensor, commenced a lawsuit against generic drug maker Par Pharmaceutical, Inc. (“Par”) ...

2015/01/27: Cosmo Pharmaceuticals S.p.A.

Cosmo communicates results of withdrawal process and time line for pre-emption rights

According to the Italian Civil Code, all shares tendered to the Company under the right of withdrawal must be re-offered to existing shareholders at the same price and in a proportional number to shares already owned.


2015/01/15: Cosmo Pharmaceuticals S.p.A.

Cosmo updates on the change of seat process and preliminary resulting pre-emption rights

110.700 shares tendered so far, final announcement on January 27, 2015...
 

2015/01/12: WILEX AG

WILEX subsidiary Heidelberg Pharma receives research grant for development of PSMA antibody drug conjugates 

WILEX AG today announced that its subsidiary Heidelberg Pharma has been awarded a research grant for the further development of PSMA-antibody drug conjugates (ADCs) to treat prostate cancer.